Knee News and Research

RSS

Blood flow restriction combined with resistance exercise can increase muscle-mass in older men

For years, researchers have known that resistance exercise training -such as weightlifting, in which muscles work against gravity or another force - can be one of the most effective ways to fight the debilitating muscle loss caused by aging.

15 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Osiris Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 May 2010

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.

5 May 2010

Surgeons can now customize artificial knee implants, prevent future revision surgeries

Throughout the years orthopedic surgeons have learned that one size does not fit all when it comes to joint replacements. Because of advancements in technology, surgeons can now customize artificial knee implants and prevent future revision surgeries.

4 May 2010

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

A recent study determined that African-Americans were less likely to have a varus thrust, but more likely to have valgus thrust than Caucasians. Varus thrust is visualized during gait as the worsening or abrupt onset of varus (bow-legged) alignment as the leg accepts weight, with a return to less varus and more neutral alignment during lift-off of the foot and the swing phase of gait.

3 May 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

$Ageing population prone to bone fractures drives South African joint replacement market$

Ageing population prone to bone fractures drives South African joint replacement market

The joint replacement market in South Africa is set to experience continued growth in the medium to long term, driven by an ageing population that is prone to cartilage degeneration and bone fractures. The introduction of innovative products with enhanced durability and longevity as well as safer operation techniques is further boosting growth in this market.

29 Apr 2010

Nuvo Research's PENNSAID now available in U.S. pharmacies

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.

27 Apr 2010

MicroStockProfit.com announces investment report featuring BioElectronics

MicroStockProfit.com announces an investment report featuring BioElectronics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

27 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

As hip replacement steadily increasing, patients need to know the facts before procedure: Surgeons

On the golf course, in the garden, or at the shopping mall, most people want to stay active, regardless of age. As the number of Americans reaching their 60s grows daily, the demand for mobility-restoring procedures, such as hip replacement, is steadily increasing.

24 Apr 2010

Knee News and Research

Blood flow restriction combined with resistance exercise can increase muscle-mass in older men

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Bovie Medical first-quarter revenues decrease to $5.6M

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Genzyme to initiate $2 billion stock buyback

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

CSI fiscal third-quarter revenue increases 9% to $16.5 million

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Additional pivotal Phase 3 trial data for MoxDuo IR released

Surgeons can now customize artificial knee implants, prevent future revision surgeries

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

REGN reports net loss of $30.5M for first-quarter 2010

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Ageing population prone to bone fractures drives South African joint replacement market

Nuvo Research's PENNSAID now available in U.S. pharmacies

MicroStockProfit.com announces investment report featuring BioElectronics

Covidien introduces PENNSAID to the U.S. market

As hip replacement steadily increasing, patients need to know the facts before procedure: Surgeons

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News